Skip to main content

IRulya Therapeutics Inc.

IRLA
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001662774

No open-market purchases or sales by IRulya Therapeutics Inc. insiders were filed in the last 90 days; 32 institutions reported holding it in 13F filings for Q3 2026, worth $66.8M in total; no superinvestor holds it.

Key figures

Market capClose on Nov 18, 2026
$440.1M
Insider buysOpen market, last 90 days
0
Insider sellsOpen market, last 90 days
0
13F holdersQ3 2026, +6 vs. previous quarter
32
13F valueReported value at the end of Q3 2026
$66.8M
Superinvestors holdingAt the end of Q3 2026
0

Price chart

From SEC filings, in USD.

Revenue, FY2025
–
No comparable prior period
Net income, FY2025
-$84.0M
No comparable prior period
Free cash flow, FY2025
-$41.8M
No comparable prior period
Revenue, Q3 FY2026
–
No comparable prior period

Short interest

See short data

From FINRA, settlement date Oct 30, 2026.

Short interest
127.8K
Shares sold short
Change
−26.9K
−17.4% vs. previous
Days to cover
1.13
At average daily volume

Superinvestors holding IRLA, Q3 2026

Go to the superinvestors tab

No superinvestor reported holding IRLA at the end of Q3 2026.

Latest insider trades

See all insider trades

Open-market purchases and sales by IRulya Therapeutics Inc. insiders from Form 4, newest first.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Dec 29, 2025 (view filing)Dec 263 daysBenatti LucaDirectorSSale−50.0K$3.47−$173.5K−56.1%39.2K after
Sep 3, 2024 (view filing)Aug 29-305 daysThye DirkCEO AND CHIEF MEDICAL OFFICERPPurchase+154.5K$0.695+$107.4K+22.4%843.9K after2 lots
Aug 22, 2024 (view filing)Aug 202 daysRyan Charles S.PRESIDENTPPurchase+48.4K$0.65+$31.5K+65.3%122.5K after
Aug 21, 2024 (view filing)Aug 19-212 daysHannah BrendanCHIEF BUSINESS OFFICER AND COOPPurchase+38.9K$0.6209+$24.2K+15.1%296.5K after6 lots
Dec 14, 2023 (view filing)Dec 12-142 daysLamond DavidDirectorPPurchase+45.6K$1.02+$46.5K+2.0%2.35M after3 lots
Dec 14, 2023 (view filing)Dec 122 daysLamond DavidDirectorPPurchase+22.3K$1.02+$22.8K+1.0%2.30M after
Dec 7, 2023 (view filing)Dec 5-72 daysLamond DavidDirectorPPurchase+57.4K$1.01+$58.1K+2.6%2.28M after3 lots
Dec 1, 2023 (view filing)Nov 29-Dec 12 daysLamond DavidDirectorPPurchase+43.1K$0.94+$40.5K+2.0%2.22M after3 lots
Aug 31, 2023 (view filing)Aug 30-311 dayLamond DavidDirectorPPurchase+82.1K$1.32+$107.9K+3.9%2.18M after2 lots
Aug 17, 2023 (view filing)Aug 15-172 daysLamond DavidDirectorPPurchase+250.0K$1.30+$325.7K+13.5%2.10M after3 lots

Top 10 13F holders, Q3 2026

See all 32 holders

The largest institutional positions in IRulya Therapeutics Inc. at the end of Q3 2026; share changes are against Q2 2026.

Institutions holding IRLA in Q3 2026
InstitutionSharesValue% of portfolioChange in sharesAction
Janus Henderson Group PLC1,714,957$53.2M0.02%+1,714,957New
Ikarian Capital, LLC95,652$2.97M0.59%+23,401+32.4%Added
Squadron Capital Management LLC90,000$2.79M0.83%+49,625+122.9%Added
Millennium Management LLC72,254$2.24M0.00%+1,475+2.1%Added
Acuta Capital Partners, LLC52,918$1.64M1.27%+52,918New
Birchview Capital, LP40,601$1.26M0.73%+40,601New
Boothbay Fund Management, LLC21,291$660.2K0.01%+7,380+53.1%Added
Jane Street Group, LLC20,156$625.0K0.00%+7,514+59.4%Added
Seven Fleet Capital Management LP11,989$371.8K0.07%+11,989New
Geode Capital Management, LLC9,741$302.1K0.00%+9,741New

Holders of 5% or more of IRLA

See all 8 holders and filings

Holders whose latest Schedule 13D or 13G filing reports 5% or more of IRulya Therapeutics Inc..

Largest holders of IRLA from 13D and 13G filings
HolderLatest formStakeChangeFirst filedLatest filingFiling
Group One Trading, L.P.13G10.70%5.94M sharesNewMar 5, 20261 filingMar 5, 2026SEC
Cormorant Asset Management, LP13G9.99%108.0K sharesNewAug 14, 20261 filingAug 14, 2026SEC
Balyasny Asset Management LLC13G/A9.99%101.6K shares0.00 ppfrom 9.99%Aug 14, 20262 filingsNov 16, 2026SEC
Squadron Capital Management LLC13G/A8.80%90.0K shares+3.20 ppfrom 5.60%Aug 4, 20262 filingsNov 16, 2026SEC
Perceptive Advisors LLC13G8.40%912.9K sharesNewOct 14, 20261 filingOct 14, 2026SEC